

<p style="text-align: center;"><b>REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL</b></p> <p>Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995. See The American Inventors Protection Act of 1999 (AIPA).</p>	<i>Application Number</i>	09/754,775
	<i>Filing Date</i>	January 4, 2001
	<i>First Named Inventor</i>	David J. Grainger
	<i>Confirmation Number</i>	6351
	<i>Group Art Unit</i>	1628
	<i>Examiner Name</i>	Jennifer Kim
	<i>Attorney Docket Number</i>	295.009US3
	<i>Customer No.</i>	21186

This is a Request for Continued Examination (RCE) under 37 C.F.R § 1.114 of the above-identified application  
entitled  
PREVENTION AND TREATMENT OF CARDIOVASCULAR PATHOLOGIES WITH TAMOXIFEN  
ANALOGUES

1. Submission required under 37 C.F.R. § 1.114:

- ☒ Response Under 37 C.F.R § 1.116 (17 pages) is enclosed.
- ☒ Information Disclosure Statement (2 pages), Form 1449 (2 pages), and copies of cited documents (34).
- ☒ Petition for Extension of Time (1 pg.).
- ☒ Copy of Declaration Under 37 C.F.R. 1.132 (4 pgs.).

2. Fees

- ☒ Authorization to charge deposit account 19-0743 in the amount of \$810.00 to pay the RCE filing fee required under 37 C.F.R. § 1.17(e).
- ☒ Authorization to charge deposit account 19-0743 in the amount of \$130.00 to pay the extension of time fee.
- ☒ **The Commissioner is hereby authorized to charge any additional fees or credit overpayment to Deposit Account No. 19-0743.**

SCHWEGMAN, LUNDBERG & WOESSNER, P.A.

By: /Janet E. Embretson/

Janet E. Embretson  
Reg. No. 39,665

CERTIFICATE UNDER 37 C.F.R 1.8: The undersigned hereby certifies that this correspondence is being filed using the USPTO's electronic filing system EFS-Web, and is addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 12th day of February, 2010.

DAWN M. POOLE

\_\_\_\_\_  
Name

*/ Dawn M. Poole /*

\_\_\_\_\_  
Signature